MAGA, GIOVANNI
 Distribuzione geografica
Continente #
AS - Asia 5.127
NA - Nord America 2.568
EU - Europa 1.246
SA - Sud America 858
AF - Africa 102
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.911
Nazione #
US - Stati Uniti d'America 2.466
SG - Singapore 2.272
CN - Cina 1.177
BR - Brasile 708
VN - Vietnam 525
HK - Hong Kong 505
IT - Italia 472
FR - Francia 286
KR - Corea 228
NL - Olanda 165
IN - India 88
JP - Giappone 88
GB - Regno Unito 71
DE - Germania 66
AR - Argentina 55
FI - Finlandia 43
BD - Bangladesh 38
MX - Messico 36
CA - Canada 35
ZA - Sudafrica 35
IL - Israele 34
ID - Indonesia 23
IQ - Iraq 22
CO - Colombia 21
EC - Ecuador 20
ES - Italia 19
RU - Federazione Russa 17
MA - Marocco 16
SA - Arabia Saudita 15
TR - Turchia 15
VE - Venezuela 15
PK - Pakistan 14
PL - Polonia 14
UA - Ucraina 14
PE - Perù 12
UZ - Uzbekistan 12
EG - Egitto 10
JM - Giamaica 10
TW - Taiwan 10
AE - Emirati Arabi Uniti 9
AT - Austria 9
CL - Cile 9
DZ - Algeria 9
PY - Paraguay 9
RS - Serbia 9
SE - Svezia 9
KE - Kenya 8
LT - Lituania 7
PH - Filippine 7
UY - Uruguay 7
IE - Irlanda 6
KZ - Kazakistan 6
MY - Malesia 6
AL - Albania 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
TN - Tunisia 5
AU - Australia 4
AZ - Azerbaigian 4
GR - Grecia 4
NP - Nepal 4
TH - Thailandia 4
BG - Bulgaria 3
DK - Danimarca 3
KG - Kirghizistan 3
LB - Libano 3
NG - Nigeria 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BE - Belgio 2
BO - Bolivia 2
BS - Bahamas 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
JO - Giordania 2
KW - Kuwait 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
BF - Burkina Faso 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
GG - Guernsey 1
GH - Ghana 1
GN - Guinea 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 9.892
Città #
Singapore 1.331
Santa Clara 1.069
Hefei 552
Hong Kong 497
San Jose 344
Lauterbourg 261
Seoul 221
Beijing 219
Ashburn 176
Ho Chi Minh City 171
Hanoi 131
Dallas 92
Los Angeles 91
Milan 63
Pavia 52
São Paulo 51
Buffalo 49
Tokyo 49
New York 36
Minamishinagawa 32
Da Nang 27
Naples 26
Rome 26
Bengaluru 25
Haiphong 25
Frankfurt am Main 22
Helsinki 22
Rio de Janeiro 22
Belo Horizonte 17
Johannesburg 17
Biên Hòa 16
Lappeenranta 16
Brasília 15
Porto Alegre 14
Guangzhou 13
Turin 13
Dhaka 12
Brooklyn 11
Council Bluffs 11
Curitiba 11
Lima 11
Tashkent 11
Fortaleza 10
Hải Dương 10
Mumbai 10
Portsmouth 10
Thái Bình 10
Bologna 9
Chicago 9
Düsseldorf 9
Guarulhos 9
Montreal 9
Orem 9
Quito 9
Bắc Ninh 8
Cape Town 8
Casablanca 8
Chennai 8
Florence 8
Goiânia 8
Lonato 8
Palermo 8
Toronto 8
Atlanta 7
Campinas 7
Denver 7
Jeddah 7
Jundiaí 7
Manaus 7
Montevideo 7
Munich 7
Nairobi 7
Ninh Bình 7
Philadelphia 7
Phoenix 7
Shanghai 7
Warsaw 7
Amsterdam 6
Araxá 6
Baghdad 6
Boston 6
Dublin 6
Kingston 6
Kyiv 6
London 6
Mexico City 6
Newark 6
Nova Iguaçu 6
Phủ Lý 6
Riyadh 6
Salvador 6
Cairo 5
Can Tho 5
Canoas 5
Caxias do Sul 5
Cosenza 5
Detroit 5
Dubai 5
Elk Grove Village 5
Falkenstein 5
Totale 6.282
Nome #
AIDS: la verità negata 271
Interaction of SARS-CoV-2 Nucleocapsid Protein and Human RNA Helicases DDX1 and DDX3X Modulates Their Activities on Double-Stranded RNA 120
Batteri Spazzini e Virus che curano: come le biotecnologie riscrivono la vita 110
Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer 86
Human DNA Polymerase beta, but Not lambda, Can Bypass a 2-Deoxyribonolactone Lesion Together with Proliferating Cell Nuclear Antigen 82
DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective 80
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors 79
The power of enzyme kinetics in the drug development process 78
Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants. 75
Synergistic action of human RNaseH2 and the RNA helicase-nuclease DDX3X in processing R-loops 75
Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes 74
Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents 71
Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity 70
Parallel solution-phase synthesis of 4-dialkylamino-2-methylsulfonyl-6-vinylpyrimidines. 70
Arylthiopyrrole (AThP) Derivatives as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Structure-Activity Relationships, and Docking Studies (Part 2). 67
Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. 67
Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. 67
Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates. 67
Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the 66
A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping 65
Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line 64
New nucleotide-competitive non-nucleoside inhibitors of terminal deoxynucleotidyl transferase: Discovery, characterization, and crystal structure in complex with the target 64
La proteina Vif del virus HIV-1 e un fattore accessorio per la trascrittasi inversa 63
p15PAF binding to PCNA modulates the DNA sliding surface 63
Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective 62
Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1. A dynamic exchange of partners. 61
Ribonucleotide incorporation by human DNA polymerase eta impacts translesion synthesis and RNase H2 activity 61
Novel alternative ribonucleotide excision repair pathways in human cells by DDX3X and specialized DNA polymerases 61
Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses 61
A role for human dna polymerase λ in alternative lengthening of telomeres 59
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor 58
New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains 57
Targeting ddx3x helicase activity with ba103 shows promising therapeutic effects in preclinical glioblastoma models 57
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 56
Error-free bypass of 2-hydroxyadenine by human DNA polymerase lambda with Proliferating Cell Nuclear Antigen and Replication Protein A in different sequence contexts. 55
Synthesis and Biological Investigation of Peptidomimetic SARS-CoV-2 Main Protease (Mpro) Inhibitors Bearing Quinoline-based Heterocycles at P3. 55
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. 54
Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor 54
A Motif Unique to the Human Dead-Box Protein DDX3 Is Important for Nucleic Acid Binding, ATP Hydrolysis, RNA/DNA Unwinding and HIV-1 Replication. 54
Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. 53
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4- d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme 53
Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation 53
Indolylarylsulfones Bearing Natural and Unnatural Amino Acids. Discovery of Potent Inhibitors of HIV-1 Non-Nucleoside Wild Type and Resistant Mutant Strains Reverse Transcriptase and Coxsackie B4 Virus 52
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment 52
Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins 51
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinoma 51
Intrinsic and extrinsic determinants of DNA polymerases fidelity in normal and translesion synthesis 50
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors 50
DDX3X Inhibitors, an Effective Way to Overcome HIV-1 Resistance Targeting Host Proteins 50
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIII beta) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses 50
DNA polymerase l interacts with PCNA in normal and translesion DNA synthesis 49
Novel Insights into the Biochemical Mechanism of CK1epsilon and its Functional Interplay with DDX3X 49
DNA Polymerases lambda and beta: The Double-Edged Swords of DNA Repair. 48
Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphosphate as substrate. 48
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies 47
CHARACTERIZATION OF MIR-1307 BY MICROARRAYS ANALYSIS 47
High flexibility of rnaseh2 catalytic activity with respect to non-canonical dna structures 47
Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional Effect 46
Lack of stereospecificity of some cellular and viral enzymes involved in the synthesis of deoxyribonucleotides and DNA: molecular basis for the antiviral activity of unnatural L-beta-nucleosides. 46
Kinetic studies with N2-phenylguanines and with L-thymidine indicate that herpes simplex virus type-1 thymidine kinase and thymidylate kinase share a common active site. 45
The 2009 Influenza Pandemic: Promising Lessons for Antiviral Therapy For Future Outbreaks. 45
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors 45
8-oxo-guanine bypass by human DNA polymerases in the presence of auxiliary proteins. 44
The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA. 44
Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. 43
4-Trifluoromethyl bithiazoles as broad-spectrum antimicrobial agents for virus-related bacterial infections or co-infections 43
Effect of alpha-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3H)-ones 43
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma 43
The PDZ-Ligand and Src-Homology Type 3 Domains of Epidemic Avian Influenza Virus NS1 Protein Modulate Human Src Kinase Activity during Viral Infection. 43
Synthesis and Biological Properties of Novel 2-Aminopyrimidin-4(3H)-ones Highly Potent against HIV-1 Mutant Strains. 43
Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. 42
Second generation PBOs show enantioselective binding to the catalytic complex of HIV-1 RT wt and drug resistant mutants. 42
Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. 42
How to win the HIV-1 drug resistance hurdle race: Running faster or jumping higher? 42
Functional domains of human DNA polymerase l: a molecular anatomy approach 41
Silencing of human DNA polymerase lambda causes replication stress and is synthetically lethal with an impaired S phase checkpoint. 41
Synthesis and antiviral activity of novel 1,3,4-thiadiazole inhibitors of DDX3x 41
Synthesis and biological activity evaluation of 3-(hetero) arylideneindolin-2-ones as potential c-Src inhibitors 41
Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. 41
Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide. 41
DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection 41
Mutations coferring interclass antiretroviral drug resistance and their impact on HIV-1 replicative capacity 40
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 40
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. 39
Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors 39
DNA polymerases: discovery, characterization and functions in cellular DNA transactions 39
Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1 38
Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents. 38
Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models. 38
Oxidative DNA Damage Bypass in Arabidopsis thaliana Requires DNA Polymerase {lambda} and Proliferating Cell Nuclear Antigen 2. 38
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. 38
PCNA, PARP-1 and p21: a dynamic exchange of partners. 37
Targeting the Human DEAD-Box Polypeptide 3 (DDX3) RNA Helicase as a Novel Strategy to Inhibit Viral Replication. 37
Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass. 36
Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. 36
Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. 36
Novel host-pathogen interactions between human proteins and NS1 of epidemic avian influenza virus 36
Diarylpyrimidine-Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. 36
Towards novel S-DABOC inhibitors: Synthesis, biological investigation, and molecular modeling studies. 36
Substrate-Induced Stable Enzyme-Inhibitor Complex Formation Allows Tight Binding of Novel 2-Aminopyrimidin-4(3H)-ones to Drug-Resistant HIV-1 Reverse Transcriptase Mutants. 36
Totale 5.500
Categoria #
all - tutte 31.975
article - articoli 26.512
book - libri 987
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 121
Totale 59.595


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202433 0 0 0 0 0 0 0 0 27 1 2 3
2024/20254.161 11 23 290 164 1.002 239 63 158 146 189 983 893
2025/20265.881 371 601 667 919 1.093 195 956 324 251 336 168 0
Totale 10.075